Featured Research

from universities, journals, and other organizations

No benefit of double dose antiviral drug for severe influenza, study suggests

Date:
May 30, 2013
Source:
BMJ-British Medical Journal
Summary:
There are no virological or clinical benefits of giving double doses of the antiviral drug oseltamivir (Tamiflu) to patients admitted to hospital with severe influenza, finds a large study from South East Asia.

This is the first study to examine the effectiveness of higher doses of oseltamivir in cases of hospitalized severe human influenza (seasonal, pandemic and bird flu strains). The authors say their findings have implications for global guidelines, clinical management and pandemic preparedness, including for the current H7N9 outbreak.

Human influenza is usually a self-limiting illness. Occasionally, however, it can lead to respiratory complications, admission to hospital, and death. Some studies suggest that, if given early, oseltamivir can help reduce mortality. This has led to suggestions to use double doses of the drug for severe influenza.

So researchers at the South East Asian Infectious Disease Clinical Research Network investigated whether double dose oseltamivir improves outcomes compared with the standard dose in patients admitted to hospital with severe influenza.

The study took place between April 2007 and February 2010 and involved 326 patients (mostly children aged under 15) with severe influenza at 13 hospitals in Indonesia, Singapore, Thailand and Vietnam.

Patients received either standard dose oseltamivir (75 mg twice a day or children's equivalent) or double dose (150 mg twice a day or children's equivalent) for five days. Nose and throat swabs were then taken to test for virus levels.

Other outcomes including death, admission to intensive care, and help with breathing (mechanical ventilation) were also assessed.

The researchers found no differences between the treatment groups in virus levels on day five. There were also no differences in deaths or rates of adverse events between the different doses.

The investigators say that the results "do not support routine use of double dose oseltamivir to treat severe influenza." And they conclude: "There are no virological or clinical advantages with double dose oseltamivir compared with standard dose in patients with severe influenza admitted to hospital."

In an accompanying editorial, Ian Barr and Aeron Hurt from the WHO Collaborating Centre for Reference and Research on Influenza say, despite some study limitations, what is clear is that double dose oseltamivir "is unlikely to significantly improve the clinical outcomes of severe cases of seasonal influenza."

These findings "could help to preserve oseltamivir stocks during a future pandemic … if clinicians were to prescribe only regular rather than double doses," they add. However, they stress that treatment options for patients with severe influenza "still need to be expanded" and that future studies "will hopefully lead to more effective treatments or better combinations of drugs."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "No benefit of double dose antiviral drug for severe influenza, study suggests." ScienceDaily. ScienceDaily, 30 May 2013. <www.sciencedaily.com/releases/2013/05/130530192427.htm>.
BMJ-British Medical Journal. (2013, May 30). No benefit of double dose antiviral drug for severe influenza, study suggests. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2013/05/130530192427.htm
BMJ-British Medical Journal. "No benefit of double dose antiviral drug for severe influenza, study suggests." ScienceDaily. www.sciencedaily.com/releases/2013/05/130530192427.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins